Loading…

Pharmacokinetic drug interaction profiles of proton pump inhibitors

Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these d...

Full description

Saved in:
Bibliographic Details
Published in:Drug safety 2006-01, Vol.29 (9), p.769-784
Main Authors: BLUME, Henning, DONATH, Frank, WARNKE, André, SCHUG, Barbara S
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23
cites cdi_FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23
container_end_page 784
container_issue 9
container_start_page 769
container_title Drug safety
container_volume 29
creator BLUME, Henning
DONATH, Frank
WARNKE, André
SCHUG, Barbara S
description Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these disorders raises the potential for clinically significant drug interactions in patients receiving proton pump inhibitors and other medications. Therefore, it is important to understand the mechanisms for drug interactions in this setting. Proton pump inhibitors can modify the intragastric release of other drugs from their dosage forms by elevating pH (e.g. reducing the antifungal activity of ketoconazole). Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Although interactions based on the change of gastric pH are a group-specific effect and thus may occur with all proton pump inhibitors, individual proton pump inhibitors differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole have been studied most extensively. A number of studies have shown that omeprazole carries a considerable potential for drug interactions, since it has a high affinity for CYP2C19 and a somewhat lower affinity for CYP3A4. In contrast, pantoprazole appears to have lower potential for interactions with other medications. Although the interaction profiles of esomeprazole, lansoprazole and rabeprazole have been less extensively investigated, evidence suggests that lansoprazole and rabeprazole seem to have a weaker potential for interactions than omeprazole. Although only a few drug interactions involving proton pump inhibitors have been shown to be of clinical significance, the potential for drug interactions should be taken into account when choosing a therapy for gastric acid-related disorders, especially for elderly patients in whom polypharmacy is common, or in those receiving a concomitant medication with a narrow therapeutic index.
doi_str_mv 10.2165/00002018-200629090-00002
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_20175553</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A200410661</galeid><sourcerecordid>A200410661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23</originalsourceid><addsrcrecordid>eNptkUtPxSAQhVlovL7-gmlidFeFUmi7NDe-EhNd6JpMYVC0LVdoF_57qfeqMREWkJPvTGbmEJIxelYwKc5pOgVldV5QKouGNjT_krbILmWszEXD5ILsxfia1LqQ9Q5ZMNmUZSP5Llk-vEDoQfs3N-DodGbC9Jy5YcQAenR-yFbBW9dhzLyd_-MsTf0qMS-udaMP8YBsW-giHm7effJ0dfm4vMnv7q9vlxd3uRa0GvMKWwRRyRZN0-qyEMLwGrhg3FaUNyjRADBhUVrLKqmBtcCNFWBEidYUfJ-cruumNt4njKPqXdTYdTCgn6JKW6iEEDyBx2vwGTpUbrB-TNPMsLpIWyoZlZIl6uwfKl2DvdN-wHnsv4Z6bdDBxxjQqlVwPYQPxaias1DfWaifLNZSsh5tWp_aHs2vcRNEAk42AEQNnQ0waBd_uZrRoqwq_gmMfJNZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20175553</pqid></control><display><type>article</type><title>Pharmacokinetic drug interaction profiles of proton pump inhibitors</title><source>Springer Link</source><creator>BLUME, Henning ; DONATH, Frank ; WARNKE, André ; SCHUG, Barbara S</creator><creatorcontrib>BLUME, Henning ; DONATH, Frank ; WARNKE, André ; SCHUG, Barbara S</creatorcontrib><description>Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these disorders raises the potential for clinically significant drug interactions in patients receiving proton pump inhibitors and other medications. Therefore, it is important to understand the mechanisms for drug interactions in this setting. Proton pump inhibitors can modify the intragastric release of other drugs from their dosage forms by elevating pH (e.g. reducing the antifungal activity of ketoconazole). Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Although interactions based on the change of gastric pH are a group-specific effect and thus may occur with all proton pump inhibitors, individual proton pump inhibitors differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole have been studied most extensively. A number of studies have shown that omeprazole carries a considerable potential for drug interactions, since it has a high affinity for CYP2C19 and a somewhat lower affinity for CYP3A4. In contrast, pantoprazole appears to have lower potential for interactions with other medications. Although the interaction profiles of esomeprazole, lansoprazole and rabeprazole have been less extensively investigated, evidence suggests that lansoprazole and rabeprazole seem to have a weaker potential for interactions than omeprazole. Although only a few drug interactions involving proton pump inhibitors have been shown to be of clinical significance, the potential for drug interactions should be taken into account when choosing a therapy for gastric acid-related disorders, especially for elderly patients in whom polypharmacy is common, or in those receiving a concomitant medication with a narrow therapeutic index.</description><identifier>ISSN: 0114-5916</identifier><identifier>DOI: 10.2165/00002018-200629090-00002</identifier><identifier>PMID: 16944963</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Anti-Ulcer Agents - adverse effects ; Anti-Ulcer Agents - metabolism ; Anti-Ulcer Agents - pharmacokinetics ; Biological and medical sciences ; Cytochrome P-450 CYP2D6 - drug effects ; Digestive system ; Drug Interactions ; Enzyme Inhibitors - adverse effects ; Enzyme Inhibitors - metabolism ; Enzyme Inhibitors - pharmacokinetics ; Esomeprazole ; Gastric Acid ; Humans ; Medical sciences ; Omeprazole - adverse effects ; Omeprazole - metabolism ; Omeprazole - pharmacokinetics ; Pharmacology. Drug treatments ; Proton Pump Inhibitors</subject><ispartof>Drug safety, 2006-01, Vol.29 (9), p.769-784</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23</citedby><cites>FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18102477$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16944963$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BLUME, Henning</creatorcontrib><creatorcontrib>DONATH, Frank</creatorcontrib><creatorcontrib>WARNKE, André</creatorcontrib><creatorcontrib>SCHUG, Barbara S</creatorcontrib><title>Pharmacokinetic drug interaction profiles of proton pump inhibitors</title><title>Drug safety</title><addtitle>Drug Saf</addtitle><description>Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these disorders raises the potential for clinically significant drug interactions in patients receiving proton pump inhibitors and other medications. Therefore, it is important to understand the mechanisms for drug interactions in this setting. Proton pump inhibitors can modify the intragastric release of other drugs from their dosage forms by elevating pH (e.g. reducing the antifungal activity of ketoconazole). Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Although interactions based on the change of gastric pH are a group-specific effect and thus may occur with all proton pump inhibitors, individual proton pump inhibitors differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole have been studied most extensively. A number of studies have shown that omeprazole carries a considerable potential for drug interactions, since it has a high affinity for CYP2C19 and a somewhat lower affinity for CYP3A4. In contrast, pantoprazole appears to have lower potential for interactions with other medications. Although the interaction profiles of esomeprazole, lansoprazole and rabeprazole have been less extensively investigated, evidence suggests that lansoprazole and rabeprazole seem to have a weaker potential for interactions than omeprazole. Although only a few drug interactions involving proton pump inhibitors have been shown to be of clinical significance, the potential for drug interactions should be taken into account when choosing a therapy for gastric acid-related disorders, especially for elderly patients in whom polypharmacy is common, or in those receiving a concomitant medication with a narrow therapeutic index.</description><subject>Anti-Ulcer Agents - adverse effects</subject><subject>Anti-Ulcer Agents - metabolism</subject><subject>Anti-Ulcer Agents - pharmacokinetics</subject><subject>Biological and medical sciences</subject><subject>Cytochrome P-450 CYP2D6 - drug effects</subject><subject>Digestive system</subject><subject>Drug Interactions</subject><subject>Enzyme Inhibitors - adverse effects</subject><subject>Enzyme Inhibitors - metabolism</subject><subject>Enzyme Inhibitors - pharmacokinetics</subject><subject>Esomeprazole</subject><subject>Gastric Acid</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Omeprazole - adverse effects</subject><subject>Omeprazole - metabolism</subject><subject>Omeprazole - pharmacokinetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Proton Pump Inhibitors</subject><issn>0114-5916</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNptkUtPxSAQhVlovL7-gmlidFeFUmi7NDe-EhNd6JpMYVC0LVdoF_57qfeqMREWkJPvTGbmEJIxelYwKc5pOgVldV5QKouGNjT_krbILmWszEXD5ILsxfia1LqQ9Q5ZMNmUZSP5Llk-vEDoQfs3N-DodGbC9Jy5YcQAenR-yFbBW9dhzLyd_-MsTf0qMS-udaMP8YBsW-giHm7effJ0dfm4vMnv7q9vlxd3uRa0GvMKWwRRyRZN0-qyEMLwGrhg3FaUNyjRADBhUVrLKqmBtcCNFWBEidYUfJ-cruumNt4njKPqXdTYdTCgn6JKW6iEEDyBx2vwGTpUbrB-TNPMsLpIWyoZlZIl6uwfKl2DvdN-wHnsv4Z6bdDBxxjQqlVwPYQPxaias1DfWaifLNZSsh5tWp_aHs2vcRNEAk42AEQNnQ0waBd_uZrRoqwq_gmMfJNZ</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>BLUME, Henning</creator><creator>DONATH, Frank</creator><creator>WARNKE, André</creator><creator>SCHUG, Barbara S</creator><general>Adis international</general><general>Wolters Kluwer Health, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T2</scope><scope>7U2</scope><scope>7U7</scope><scope>C1K</scope><scope>M7N</scope></search><sort><creationdate>20060101</creationdate><title>Pharmacokinetic drug interaction profiles of proton pump inhibitors</title><author>BLUME, Henning ; DONATH, Frank ; WARNKE, André ; SCHUG, Barbara S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Anti-Ulcer Agents - adverse effects</topic><topic>Anti-Ulcer Agents - metabolism</topic><topic>Anti-Ulcer Agents - pharmacokinetics</topic><topic>Biological and medical sciences</topic><topic>Cytochrome P-450 CYP2D6 - drug effects</topic><topic>Digestive system</topic><topic>Drug Interactions</topic><topic>Enzyme Inhibitors - adverse effects</topic><topic>Enzyme Inhibitors - metabolism</topic><topic>Enzyme Inhibitors - pharmacokinetics</topic><topic>Esomeprazole</topic><topic>Gastric Acid</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Omeprazole - adverse effects</topic><topic>Omeprazole - metabolism</topic><topic>Omeprazole - pharmacokinetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Proton Pump Inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BLUME, Henning</creatorcontrib><creatorcontrib>DONATH, Frank</creatorcontrib><creatorcontrib>WARNKE, André</creatorcontrib><creatorcontrib>SCHUG, Barbara S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Safety Science and Risk</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BLUME, Henning</au><au>DONATH, Frank</au><au>WARNKE, André</au><au>SCHUG, Barbara S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacokinetic drug interaction profiles of proton pump inhibitors</atitle><jtitle>Drug safety</jtitle><addtitle>Drug Saf</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>29</volume><issue>9</issue><spage>769</spage><epage>784</epage><pages>769-784</pages><issn>0114-5916</issn><abstract>Proton pump inhibitors are used extensively for the treatment of gastric acid-related disorders because they produce a greater degree and longer duration of gastric acid suppression and, thus, better healing rates, than histamine H(2) receptor antagonists. The need for long-term treatment of these disorders raises the potential for clinically significant drug interactions in patients receiving proton pump inhibitors and other medications. Therefore, it is important to understand the mechanisms for drug interactions in this setting. Proton pump inhibitors can modify the intragastric release of other drugs from their dosage forms by elevating pH (e.g. reducing the antifungal activity of ketoconazole). Proton pump inhibitors also influence drug absorption and metabolism by interacting with adenosine triphosphate-dependent P-glycoprotein (e.g. inhibiting digoxin efflux) or with the cytochrome P450 (CYP) enzyme system (e.g. decreasing simvastatin metabolism), thereby affecting both intestinal first-pass metabolism and hepatic clearance. Although interactions based on the change of gastric pH are a group-specific effect and thus may occur with all proton pump inhibitors, individual proton pump inhibitors differ in their propensities to interact with other drugs and the extent to which their interaction profiles have been defined. The interaction profiles of omeprazole and pantoprazole have been studied most extensively. A number of studies have shown that omeprazole carries a considerable potential for drug interactions, since it has a high affinity for CYP2C19 and a somewhat lower affinity for CYP3A4. In contrast, pantoprazole appears to have lower potential for interactions with other medications. Although the interaction profiles of esomeprazole, lansoprazole and rabeprazole have been less extensively investigated, evidence suggests that lansoprazole and rabeprazole seem to have a weaker potential for interactions than omeprazole. Although only a few drug interactions involving proton pump inhibitors have been shown to be of clinical significance, the potential for drug interactions should be taken into account when choosing a therapy for gastric acid-related disorders, especially for elderly patients in whom polypharmacy is common, or in those receiving a concomitant medication with a narrow therapeutic index.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>16944963</pmid><doi>10.2165/00002018-200629090-00002</doi><tpages>16</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0114-5916
ispartof Drug safety, 2006-01, Vol.29 (9), p.769-784
issn 0114-5916
language eng
recordid cdi_proquest_miscellaneous_20175553
source Springer Link
subjects Anti-Ulcer Agents - adverse effects
Anti-Ulcer Agents - metabolism
Anti-Ulcer Agents - pharmacokinetics
Biological and medical sciences
Cytochrome P-450 CYP2D6 - drug effects
Digestive system
Drug Interactions
Enzyme Inhibitors - adverse effects
Enzyme Inhibitors - metabolism
Enzyme Inhibitors - pharmacokinetics
Esomeprazole
Gastric Acid
Humans
Medical sciences
Omeprazole - adverse effects
Omeprazole - metabolism
Omeprazole - pharmacokinetics
Pharmacology. Drug treatments
Proton Pump Inhibitors
title Pharmacokinetic drug interaction profiles of proton pump inhibitors
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T22%3A10%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacokinetic%20drug%20interaction%20profiles%20of%20proton%20pump%20inhibitors&rft.jtitle=Drug%20safety&rft.au=BLUME,%20Henning&rft.date=2006-01-01&rft.volume=29&rft.issue=9&rft.spage=769&rft.epage=784&rft.pages=769-784&rft.issn=0114-5916&rft_id=info:doi/10.2165/00002018-200629090-00002&rft_dat=%3Cgale_proqu%3EA200410661%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c507t-7ebea576bed9bc4255d38a3513f7039e6edaa15fe6ff176ca1ba3df5ad54efd23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20175553&rft_id=info:pmid/16944963&rft_galeid=A200410661&rfr_iscdi=true